Wesche Holger 4
4 · Harpoon Therapeutics, Inc. · Filed Apr 5, 2021
Insider Transaction Report
Form 4
Wesche Holger
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2021-04-01$0.60/sh+1,534$920→ 62,852 total - Exercise/Conversion
Employee Stock Option (right to buy)
2021-04-01−8,466→ 2,540 totalExercise: $0.60Exp: 2027-01-13→ Common Stock (8,466 underlying) - Exercise/Conversion
Common Stock
2021-04-01$0.60/sh+8,466$5,080→ 61,318 total - Sale
Common Stock
2021-04-01$21.14/sh−500$10,570→ 52,852 total - Sale
Common Stock
2021-04-01$20.41/sh−9,500$193,921→ 53,352 total - Exercise/Conversion
Employee Stock Option (right to buy)
2021-04-01−1,534→ 31,002 totalExercise: $0.60Exp: 2026-04-06→ Common Stock (1,534 underlying)
Footnotes (5)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- [F2]Represents the weighted average sales price per share. The shares sold at prices ranging from $20.00 to $20.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- [F3]Represents the weighted average sales price per share. The shares sold at prices ranging from $21.08 to $21.30 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- [F4]The stock option vested and became exercisable as to 25% of the shares subject to the option on May 24, 2017, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the options are 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
- [F5]The stock option vested and became exercisable as to 25% of the shares subject to the option on April 6, 2017, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.